JP2008536929A - 生体強化組成物 - Google Patents

生体強化組成物 Download PDF

Info

Publication number
JP2008536929A
JP2008536929A JP2008507777A JP2008507777A JP2008536929A JP 2008536929 A JP2008536929 A JP 2008536929A JP 2008507777 A JP2008507777 A JP 2008507777A JP 2008507777 A JP2008507777 A JP 2008507777A JP 2008536929 A JP2008536929 A JP 2008536929A
Authority
JP
Japan
Prior art keywords
composition
valsartan
agent
arb
dissolution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008507777A
Other languages
English (en)
Japanese (ja)
Inventor
ナゲシュ・アール・パレプ
プラティバ・エス・ピルガオンカー
マハルク・ティー・ルストムジー
アニルクマー・エス・ガンディ
パラス・アール・ジャイン
Original Assignee
ルビコン・リサーチ・ピーヴィーティー・エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルビコン・リサーチ・ピーヴィーティー・エルティーディー filed Critical ルビコン・リサーチ・ピーヴィーティー・エルティーディー
Publication of JP2008536929A publication Critical patent/JP2008536929A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008507777A 2005-04-18 2006-04-18 生体強化組成物 Pending JP2008536929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN477MU2005 2005-04-18
IN315MU2006 2006-03-06
PCT/US2006/014422 WO2006113631A2 (fr) 2005-04-18 2006-04-18 Compositions ameliorees biologiquement

Publications (1)

Publication Number Publication Date
JP2008536929A true JP2008536929A (ja) 2008-09-11

Family

ID=37115820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507777A Pending JP2008536929A (ja) 2005-04-18 2006-04-18 生体強化組成物

Country Status (8)

Country Link
EP (1) EP1877042A4 (fr)
JP (1) JP2008536929A (fr)
KR (1) KR20080042039A (fr)
AU (1) AU2006236497A1 (fr)
CA (1) CA2605183A1 (fr)
IL (1) IL186721A0 (fr)
MX (1) MX2007012947A (fr)
WO (1) WO2006113631A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155302A (ja) * 2007-12-27 2009-07-16 Ind Technol Res Inst 徐放性組成物およびその製造方法
JP2012530778A (ja) * 2009-06-25 2012-12-06 ジン ヤン ファーム カンパニー リミテッド ロサルタンカルボン酸を含有する薬学組成物及びその製造方法
WO2014119667A1 (fr) 2013-01-30 2014-08-07 沢井製薬株式会社 Composition pharmaceutique contenant du candésartan cilexétil
JP2015506980A (ja) * 2012-02-08 2015-03-05 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジンの緩和放出製剤

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007077581A2 (fr) * 2006-01-02 2007-07-12 Rubicon Research Private Limited Compositions pharmaceutiques
KR20090049089A (ko) * 2006-09-05 2009-05-15 아스트라제네카 아베 칸데사르탄 실렉세틸을 포함하는 약학 조성물
EA026213B1 (ru) * 2006-10-20 2017-03-31 Солвей Фармасьютикалс Б.В. Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
WO2008064338A2 (fr) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Formulation de valsartan pour administration pulsatile
US20100041644A1 (en) * 2006-11-28 2010-02-18 Laboratorios Liconsa, S. A. Stabilized solid pharmaceutical composition of candesartan cilexetil
AU2007333355B2 (en) * 2006-12-05 2011-10-20 Novartis Ag Microemulsion dosage forms of valsartan and methods of making the same
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
WO2008084504A2 (fr) * 2007-01-12 2008-07-17 Rubicon Research Private Limited Composition pharmaceutique d'inhibiteurs du récepteur de l'angiotensine ii
DE202008018063U1 (de) * 2007-04-25 2011-10-11 Teva Pharmaceutical Industries Ltd. Pharmazeutischer Hilfsstoffkomplex
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
KR20100046216A (ko) * 2007-08-01 2010-05-06 테바 파마슈티컬 인더스트리즈 리미티드 칸데사르탄의 약학 조성물
CA2701695A1 (fr) * 2007-10-09 2009-04-16 Novartis Ag Formulation pharmaceutique de valsartan
AU2008313620A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product containing N-aryl urea-based compound
WO2009084040A1 (fr) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Formule d'antagonistes des récepteurs de l'angiotensine administrée une fois par jour
US20110028526A1 (en) * 2008-02-28 2011-02-03 Amol Matharu Valsartan solid oral dosage forms and methods of making such formulations
CN102046154A (zh) * 2008-06-03 2011-05-04 诺瓦提斯公司 缬沙坦的脉冲释放
SI2165702T1 (sl) 2008-09-17 2012-05-31 Helm Ag Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2011028016A2 (fr) * 2009-09-04 2011-03-10 한올바이오파마주식회사 Préparation pharmaceutique comprenant des agents bêtabloquants et des agents bloquants du récepteur de l'angiotensine ii
WO2014088123A1 (fr) 2012-12-05 2014-06-12 Sawai Pharmaceutical Co., Ltd. Préparation contenant du candésartan cilexétil
WO2016005994A2 (fr) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Composition pharmaceutique comprenant une dispersion solide de médicaments de classe ii bcs avec gelucires
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
BR122022005778B1 (pt) 2017-10-04 2024-01-09 Celgene Corporation Cápsula compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carboxamida
CN109350609A (zh) * 2018-11-14 2019-02-19 常州大学 一种壳聚糖包裹玉米醇溶蛋白纳米粒的制备及负载金合欢素钠盐的应用
CN113933472B (zh) * 2020-06-29 2024-07-09 武汉武药科技有限公司 测定替米沙坦固体制剂溶出度的溶出介质及其应用
CN112516105A (zh) * 2020-12-10 2021-03-19 成都恒瑞制药有限公司 一种氯沙坦钾口服制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002348A (ja) * 2002-03-27 2004-01-08 Bayer Yakuhin Ltd 小型化されたニフェジピン有核錠剤
WO2004105694A2 (fr) * 2003-05-22 2004-12-09 Lipocine, Inc. Compositions pharmaceutiques et formes posologiques pour l'administration de medicaments hydrophobes
JP2006511542A (ja) * 2002-12-18 2006-04-06 ノバルティス アクチエンゲゼルシャフト バルサルタンとｃｏｘ−２インヒビターの組み合わせ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
HRP20031029A2 (en) * 2003-12-12 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of inclusion complexes of valsartan with?-cylodextrin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002348A (ja) * 2002-03-27 2004-01-08 Bayer Yakuhin Ltd 小型化されたニフェジピン有核錠剤
JP2006511542A (ja) * 2002-12-18 2006-04-06 ノバルティス アクチエンゲゼルシャフト バルサルタンとｃｏｘ−２インヒビターの組み合わせ
WO2004105694A2 (fr) * 2003-05-22 2004-12-09 Lipocine, Inc. Compositions pharmaceutiques et formes posologiques pour l'administration de medicaments hydrophobes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012012126; 医薬品添付文書（ディオバン錠） 第６版, 2003 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155302A (ja) * 2007-12-27 2009-07-16 Ind Technol Res Inst 徐放性組成物およびその製造方法
JP2012530778A (ja) * 2009-06-25 2012-12-06 ジン ヤン ファーム カンパニー リミテッド ロサルタンカルボン酸を含有する薬学組成物及びその製造方法
JP2015506980A (ja) * 2012-02-08 2015-03-05 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジンの緩和放出製剤
WO2014119667A1 (fr) 2013-01-30 2014-08-07 沢井製薬株式会社 Composition pharmaceutique contenant du candésartan cilexétil

Also Published As

Publication number Publication date
MX2007012947A (es) 2008-04-09
CA2605183A1 (fr) 2006-10-26
WO2006113631A3 (fr) 2006-12-14
EP1877042A4 (fr) 2011-03-02
IL186721A0 (en) 2008-02-09
WO2006113631A2 (fr) 2006-10-26
EP1877042A2 (fr) 2008-01-16
KR20080042039A (ko) 2008-05-14
AU2006236497A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
JP2008536929A (ja) 生体強化組成物
JP7211644B2 (ja) ニロチニブの医薬組成物
WO2008084504A2 (fr) Composition pharmaceutique d'inhibiteurs du récepteur de l'angiotensine ii
EP2359830B1 (fr) Préparations à libération contrôlée d'oxcarbazépine disposant d'un profil à libération sigmoïdale
EP1974722A2 (fr) Formules de dosage de tacrolimus modifiées
WO2007086078A2 (fr) Compositions pharmaceutiques atypiques et processus de preparation correspondant
KR20100126465A (ko) 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
JP5351490B2 (ja) ニフェジピン含有有核錠剤およびその製法
WO2009084040A1 (fr) Formule d'antagonistes des récepteurs de l'angiotensine administrée une fois par jour
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
MX2014002163A (es) Métodos para el tratamiento de desórdenes cardiovasculares.
WO2005070398A2 (fr) Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants
JP2010502698A (ja) カンデサルタンシレキセチルを含む医薬組成物
US20090123543A1 (en) Pharmaceutical compositions
WO2013175494A2 (fr) Formulations pharmaceutiques à libération contrôlée d'inhibiteurs directs de la thrombine
KR20110015650A (ko) 발사르탄의 펄스형 방출
CN101217942A (zh) 生物增强组合物
EP2167047A2 (fr) Procédé de formation de formes posologiques orales solides dans des antagonistes du récepteur de l'angiotensine ii
EP2637695B1 (fr) Formulations d'olmesartan
KR102165548B1 (ko) 두타스테라이드가 봉입된 나노 가용화 다공체, 이를 포함하는 약학 조성물 및 이의 제조방법
US20100119607A1 (en) Bioenhanced compositions
WO2008064338A2 (fr) Formulation de valsartan pour administration pulsatile
US9675585B1 (en) Extended release pharmaceutical formulations
EP2153822A1 (fr) Granulation d'ingrédients pharmaceutiques actifs
WO2006119779A2 (fr) Composition pharmaceutique comprenant un antagoniste de l'aldosterone

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121030